Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
Based on recent breakthroughs in tumor-targeting and nanotechnology, a newgeneration of powerful biological anti-cancer agents that are exceedinglyprecise and highly selective for diseased tissues is currently in clinicaldevelopment. Anti-cancer agents such as Rexin-G(R) can be delivered by simpleintravenous infusion, yet are programmed to seek-out and accumulateselectively in primary and metastatic lesions that have spread throughout thebody, delivering a tumor-killing gene while sparing normal cells and tissues.Representing the world's first targeted genetic medicine proven to be bothsafe and effective in the clinic, Rexin-G(R) is commercially available in thePhilippines -- for use in all solid tumors that are refractory to standardchemotherapy -- and is currently in clinical trials in the USA for severaltypes of cancer.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceuticalcompany dedicated to the advancement of genetic medicine with the developmentand commercialization of its proprietary targeted delivery systems. To learnmore about our pipeline of proprietary biotechnologies currently available forclinical development and/or new product development, please visit us athttp://www.epeiusbiotech.com.
For more information about Rexin-G(R), on-going clinical trials in the USAand abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems,please contact Erlinda M. Gordon, M.D., at firstname.lastname@example.org.
*(LOGO 72dpi: Send2press.com/mediaboom/08-0421-Epeius_72dpi.jpg)
This release was issued on behalf of the above organization bySend2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
SOURCE Epeius Biotechnologies
You May Also Like